Using computer-based monitoring and intervention to prevent harmful combinations of antiretroviral drugs in the New York state AIDS drug assistance program

Joint Commission Journal on Quality and Patient Safety

Volumn 38, Issue 6, 2012, Pages 269-276

  Gonzalez, Charles J ^a   Rivera, Christine A ^a   Martin, Raymond J ^a   Mergian, Gwen A ^a   Cruz, Humberto ^b   Agins, Bruce D ^b  

^a NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^b The AIDS Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DRUG COMBINATION; DRUG CONTRAINDICATION; DRUG INTERACTION; DRUG UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION SYSTEM; INSURANCE; MEDICAL INFORMATION SYSTEM; MEDICATION ERROR; ORGANIZATION AND MANAGEMENT; POLYPHARMACY; RETROSPECTIVE STUDY; STATISTICS; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-RETROVIRAL AGENTS; CLINICAL PHARMACY INFORMATION SYSTEMS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; HIV INFECTIONS; HUMANS; INFORMATION SYSTEMS; INSURANCE CLAIM REVIEW; MEDICATION ERRORS; NEW YORK; POLYPHARMACY; RETROSPECTIVE STUDIES;

EID: 84862169774     PISSN: 15537250     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1553-7250(12)38034-3     Document Type: Article

References (25)

1. Bates DW, Gawande AA. Improving Safety with Information Technology. N Engl J Med. 2003 Jun 19;348(25):2526-2534. (Pubitemid 36706541)
2. Henry J Kaiser Family Foundation, National Alliance of State and Territorial AIDS Directors. National ADAP Monitoring Project Annual Report. Apr 2007.
3. New York State Department of Health AIDS Institute. HIV Clinical Resource. Accessed May 10, 2011. http://www.hivguidelines.org/
4. Shah S, et al. Identification of drug interactions involving ART in New York City HIV specialty clinics. Abstract 573. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, Feb 3-6, 2008.
5. Shuter J, et al. Rates of ritonavir non-adherence and dose staggering in HIV+ patients receiving RTV-boosted atazanavir or fosamprenavir. Abstract 803. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, Feb 3-6, 2008.
6. Hellinger FJ, Encinosa WE. The cost of and incidence of prescribing errors among privately insured HIV patients. Pharmacoeconomics. 2010;28(1):23-34.
7. Tierney WM. Adverse outpatient drug events: A problem and an opportunity. N Engl J Med. 2003 Apr 17;348(16):1587-1589. (Pubitemid 36437936)
8. Chertow GM, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA. 2001 Dec 12;286(22):2839-2844. (Pubitemid 33126926)
9. Hunt DL, et al. Effects of computer-based clinical decision support systems on physician performance and patient outcomes: A systematic review. JAMA. 1998 Oct 21;280(15):1339-1346. (Pubitemid 28473723)
10. Raschke RA, et al. A computer alert system to prevent injury from adverse drug events: Development and evaluation in a community teaching hospital. JAMA. 1998 Oct 21;280(15):1317-1320. (Pubitemid 28473717)
11. Kaushal R, Shojania KG, Bates DW. Effects of computerized physician order entry and clinical decision support systems on medication safety: A systematic review. Arch Intern Med 2003 Jun 23;163(12):1409-1416. (Pubitemid 36758913)
12. Gandhi TK, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003 Apr 17;348(16):1556-1564. (Pubitemid 36437933)
13. Hartshorn EA. Handbook of Drug Interactions. Hamilton, IL: Drug Intelligence Publications, 1973.
14. National Council for Prescription Drug Programs. Basic Guide to Standards. May 2010. Accessed Apr 19, 2012. http://www.ncpdp.org/pdf/Basic- guide-to-standards.pdf.
15. Liverpool HIV Pharmacology Group (LHPG), School of Biomedical Sciences, University of Liverpool. Home page. (Updated Mar 14, 2012.) Accessed Apr 19, 2012. www.hiv-druginteractions.org.
16. US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 1-239. Panel on Antiretroviral Guidelines for Adults and Adolescents. (Updated Mar 27, 2012.) Accessed Apr 19, 2012. http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf.
17. Agency for Healthcare Research and Quality. New Antiretroviral Drugs: Maraviroc, Raltegravir, Etravirine, and Rilpivirine. New York State Department of Health. Nov 8, 2011. Accessed Apr 19, 2012. http://www.guideline.gov/content. aspx?id=35093.
18. US Department of Health and Human Services, Health Resources and Services Administration. HAB HIV performance measures: ADAP: AIDS Drug Assistance Program. Dec 10, 2009. Accessed May 10, 2011. http://hab.hrsa.gov/ deliverhivaidscare/files/habpmsadap.pdf
19. Hillestad R, et al. Can electronic medical record systems transform health care? Potential health benefits, savings, and costs. Health Aff (Millwood). 2005;24(5):1103-1117. (Pubitemid 41577096)
20. Pau AK. Clinical management of drug interaction with antiretroviral agents. Curr Opin HIV AIDS. 2008;3(3):319-324. (Pubitemid 351521017)
21. Cook R, Woods D. Medical Disasters and Latent System Failures: Blame, Guilt, and Causality. Columbus, OH: Cognitive Technologies Laboratory, Ohio University State University, 1992.
22. Cook RI, Woods DD, Miller C. A Tale of Two Stories: Contrasting Views of Patient Safety. Chicago: National Patient Safety Foundation, 1998.
23. Leape LL, Berwick DM, Bates DW. What practices will most improve safety? Evidence-based medicine meets patient safety. JAMA. 2002 Jul 24; 288(4):501-507. (Pubitemid 34787485)
24. US Department of Labor, Employee Benefits Security Administration. Patient Protection and Affordable Care Act. Accessed May 10, 2011. http://www.dol.gov/ebsa/healthreform/
25. Perlin JB, Kolodner RM, Roswell RH. The Veterans Health Administration: Quality, value, accountability, and information as transforming strategies for patient-centered care. Am J Manag Care. 2004;10(11)828-836.